Norgine has announced that it acquired Theravia, an international pharmaceutical company specializing in treatments for patients with rare and debilitating conditions, from Mérieux Equity Partners.
Theravia has several products in the rare disease space, including SIKLOS®, for adults and children with sickle cell disease, and ORPHACOL®, a medicine for adults and children who have a genetic disorder that affects bile production by the liver. The development of Theravia in the past few years has been supported by its majority shareholder Mérieux Equity Partners, a healthcare dedicated investment firm based in France.
Norgine is a specialty pharmaceutical and consumer healthcare company. The company has more than €550 million (nearly $625 million USD) of annual revenues and a 120-year track record of bringing life-changing products to patients and consumers across core markets of Western Europe, Australia and New Zealand.
Theravia’s products span both the rare haematology and rare hepatology therapeutic areas and complement Norgine’s existing rare and specialty portfolio. With the acquisition of Theravia, Norgine will now have six core products in its rare disease portfolio (PEDMARQSI®, eflornithine, mavorixafor, AGILUS®, SIKLOS® and ORPHACOL®).
According to data captured in the LevinPro HC database, this marks the 15th Pharmaceuticals transaction of 2025. There were 66 Pharmaceuticals acquisitions reported in 2024, and 107 in 2023. Financial terms of the deal were not disclosed.
